Schizophrenia

Boehringer Ingelheim and Click Therapeutics have announced the launch of an expanded collaboration for development and commercialization of a second prescription digital therapeutic for those diagnosed with schizophrenia.

A nutritional program that focused on increased intake of prebiotics and probiotics improved cardiometabolic health in patients with schizophrenia spectrum disorders, according to a study published in BMC Psychiatry.

A multidiagnostic prediction model developed using deep learning was highly predictive of mental disorder diagnosis, according to new data published in JAMA Psychiatry.

An increased risk for Parkinson’s disease was associated with a range of factors, comorbidities and prodromal features, some of which may appear 5 to 10 years prior to diagnosis, according to a study in JAMA Neurology.

Teva Pharmaceuticals announced it recently completed resubmission of a new drug application to the FDA for mdc-IRM, a risperidone subcutaneous long-acting injectable for the treatment of schizophrenia.

In a cohort of United States military veterans, relapse of schizophrenia symptoms was associated with higher rates of adverse socioeconomic outcomes, according to a study published in the Journal of Clinical Psychiatry.

The FDA has accepted a new drug application for aripiprazole, a 2-month, ready-to-use, long-acting injectable for the treatment of schizophrenia in adults and maintenance monotherapy treatment of bipolar I disorder in adults.

Researchers at Aston University in England have received funding to explore new methods of recording electrical signals emitted from brain cells, which could lead to potential treatment for conditions like epilepsy and schizophrenia.

Karuna Therapeutics Inc. announced positive results from its phase 3 EMERGENT-2 trial evaluating the efficacy, safety and tolerability of its investigational therapy for adults with schizophrenia.

Despite advances in treatment, patients with schizophrenia have faced obstacles in obtaining an education, with the largest gap occurring in high-income countries, according to a study published in Lancet Psychiatry.